Despite the recently released cryo-EM structuresfor both AD and CBD tau, there are still several issues that needto be solved such as the structures of the tau-tracer complexes, thepotential binding sites of the tracers in the tau fibril as well asthe kinetics of the tracer binding to the fibril.30−33. The gene discussed is MAPT; the disease is Alzheimer disease.